A Phase III, Multicentre, Double-Blind, Placebo-Controlled Withdrawal Study in Patients With Hyperphosphatemia

NCT00416520 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

336

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease
Hyperphosphatemia

Interventions

DRUG: MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)
DRUG: Placebo
DRUG: Another phosphate binder (Sevelamer)

Sponsor

Tanabe Pharma Corporation